Life Science companies leverage Hercules' debt financing solutions to speed time to market, broaden the scope of their clinical development and research, invest in new capabilities to reach important growth milestones, or shore-up their balance sheets ahead of an IPO or negotiations with strategic partners.
Below is a select list of our portfolio companies:
Acceleron is a privately-held biopharmaceutical company that discovers, develops, manufactures and commercializes novel protein therapeutics for orphan diseases and cancer.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.
Redwood City, CAwww.acelrx.com
Adiana, a private corporation and clinically driven company, is currently sponsoring a novel, non-incisional treatment designed to prevent pregnancy.
Redwood City, CAwww.adiana.com
ADMA is a late-stage biotechnology company focused on developing specialty immune globulin therapeutics and commercialization of human plasma.
Agile Therapeutics is a women’s health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Agile’s lead product candidate, Twirla®, also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development.
Alexza Pharmaceuticals is a rapidly emerging pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS conditions.
Mountain View, CAwww.alexza.com
Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, Iluvien(R), is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien(R) is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Amedica is devoted to bringing advanced ceramics technology to those suffering from the effects of joint disease. Using its proprietary MC2 and CSC ceramics technologies, the company plans to deliver innovative implants that have superior mechanical properties, resistance to wear, and significantly improved compatibility with MRI, fluoroscopy and CT imaging systems. Amedica Corporation is an emerging leader in the design and development of innovative products for the growing, $19 billion market in orthopedic devices.
Salt Lake City, UTwww.amedicacorp.com
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform, which include topically administrered dermatologic compounds. (Acquired by Pfizer in 2016)
Palo Alto, CAwww.anacor.com
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with inflammation and autoimmune diseases.
Aprecia is an emerging pharmaceutical company that uses proprietary ZipDose Technology to transform the way people take medicine. Aprecia is the first and only company in the world to utilize 3D printing technology to develop and manufacture pharmaceutical products at commercial scale. Aprecia plans to introduce multiple products utilizing ZipDose Technology in the coming years, focusing first on the central nervous system therapeutic area, where there is a need for medicines that are easy to take. The company is privately owned, with Prasco Laboratories and its parent company, Scion Companies, holding controlling interest. For more information visit www.aprecia.com.
Aspire Bariatrics, Inc. is developing a novel obesity treatment called AspireAssist Aspiration Therapy. The AspireAssist is a new weight loss solution for people with obesity. Unlike many other weight loss procedures, it’s minimally-invasive and reversible.
King of Prussia, PAwww.aspirebariatrics.com
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology.
AVEO Oncology is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies.
BARRX Medical, Inc. is a privately-held company that develops treatment solutions for Barrett's esophagus, a precancerous condition of the lining of the esophagus (swallowing tube) caused by gastroesophageal reflux disease, or GERD.
Baxano Surgical is a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lumbar region.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
BIND Therapeutics is a clinical-stage biopharmaceutical company that seeks to significantly improve patients' lives and treat disease by developing Accurins™, targeted and programmable therapeutics that are designed to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues.
BioQuiddity is a privately held corporation focused on addressing some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQuiddity’s ultimate objective is to provide value to the healthcare community by playing a vital role in containing costs and improving quality via the Company’s proprietary unit-dose infusion systems.
San Francisco, CAwww.bioqpharma.com
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Its pipeline consists of five product candidates, including potential novel therapeutics for hyperhidrosis (excessive sweating), atopic dermatitis, allergic contact dermatitis, acne and psoriasis. Brickell’s management team and board of directors have extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. Its strategy is to leverage this experience to in-license, acquire, develop and commercialize products that Brickell believes can be successful in the dermatology marketplace. For more information, visit www.brickellbio.com.
Celator Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Celator’s proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity.
Celsion is dedicated to the development of efficient, effective and targeted therapies for the treatment of cancer.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases and intends to utilize its series of proprietary lead compounds such uses as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders.
Chapel Hill, NCwww.cempra.com
Cerecor Inc. is a Maryland-based biopharmaceutical company comprised of a team of industry experts and leading scientists focused on developing neuro-psychiatric drugs to make a difference in patients’ lives.
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.
Chroma Therapeutics is a biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches.
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative drugs to treat cancer and orphan indications and protect healthy tissues from radiation and chemotherapy.
Concert Pharmaceuticals is a clinical stage biotechnology company that leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines.
Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer.
Crux Biomedical is a private funded company focused on developing improved treatments for the prevention of pulmonary embolisms.
Menlo Park, CAcruxbiomedical.com
CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin, its improved version of the widely used chemotherapeutic agent doxorubicin, and DK049, a novel drug conjugate which is expected to enter clinical trials in 2016. CytRx is also expanding its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.
Los Angeles, CAwww.cytrx.com
Dance Biopharm is a privately-held company focused on the clinical development of inhaled insulin products to treat diabetes patients worldwide.
deCODE genetics uses its unique expertise and population resources to discover genetic risk factors for dozens of common diseases, ranging from cardiovascular disease to cancer, and is a global leader in analyzing and understanding the human genome.
Dicerna Pharmaceuticals is an RNAi-focused biopharmaceutical company developing novel therapeutic agents in multiple disease areas based on its proprietary Dicer Substrate Technology platform.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. They develop immunotherapies based on cutting-edge Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.
Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions.
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO™ ER, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet's Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, including the boxed warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.
EKOS Corporation is the world leader in providing ultrasound-accelerated, fluid infusion catheters for diagnosis and therapy.
ENTrigue Surgical, Inc. is a Texas-based company that designs, develops, manufactures and distributes medical devices used for Ear, Nose and Throat surgical procedures.
San Antonio, TXwww.entriguesurgical.com
EpiCept focuses on the unmet needs in the treatment of pain and cancer and its ASAP technology can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells.
Epirus is a publicly-traded biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies.
Everyday Health Inc. is a leading online publisher of self-help experts that focuses primarily on general health and fitness and that utilizes the Internet at the core of its publishing platform.
New York, NYwww.waterfrontmedia.com
Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene-silencing drugs against validated targets. Our 3-D, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.
Flowonix Medical, Inc. (www.flowonix.com), with offices in New
Jersey and Massachusetts, is dedicated to working with healthcare professionals
to help ease suffering associated with chronic pain and allows patients to
reclaim their lives through innovation and therapy advancements. The strategic
business goal of Flowonix Medical, Inc. is to become the leading implantable
drug delivery company in the world.
Founded in 2005, Flowonix Medical, Inc. received approval to conduct its first clinical trial in 2007 on the Prometra® programmable implantable pump. The company received approval from the FDA to market the Prometra® system in 2012. Flowonix Medical, Inc. has been granted multiple patents, and is focused on working closely with physicians to rapidly improve the capabilities of implantable drug delivery and management systems.
Mt. Olive, NJwww.flowonix.com
Guava Technologies is a biotechnology company that develops, manufactures and markets unique integrated cellular analysis systems for the life science researcher's benchtop.
Gynesonics, Inc. is a development stage company focusing on medical devices for women's health, including a system that permits the gynecologist to diagnose, target and treat multiple fibroid tumors simultaneously, while providing significant advantages over existing procedures and techniques.
Redwood City, CAwww.gynesonics.com
Home Dialysis Plus focuses on the advancement of home hemodialysis treatment for patients suffering from end-stage renal disease.
Sunnyvale , CAwww.homedialysisplus.com
Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management.
Immune Pharmaceuticals Inc., (NASDAQ: IMNP) together with its subsidiaries, is a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company focuses on a precision medicine approach to treatment of diseases by incorporating methods for better patient selection in its clinical trials and the potential for development of companion diagnostics. The Company's immuno-inflammation product pipeline includes: bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation, a portfolio of clinical-stage immune oncology products and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis.
New York, NYwww.immunepharmaceuticals.com
Insmed Incorporated (Nasdaq CM: INSM) is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases.
Monmouth Junction, NJwww.insmed.com
InspireMD is a medical device company focused on the development and commercialization of its proprietary stent system technology, Mguard for use in interventional cardiology and other vascular procedures.
Tel Aviv, Israelwww.inspire-md.com
IntegenX, headquartered in Pleasanton, California, is the market leader of Rapid human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com. IntegenX, the IntegenX logo, and RapidHIT are the registered trademarks of IntegenX Inc.
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. SB-300 is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and SB-300 contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of SB-300 in horses, and Canalevia™ for cats and dogs.
San Francisco, CAwww.jaguaranimalhealth.com
Kamada is a public biopharmaceutical company (TASE: KMDA) that develops, produces and markets a line of specialty life-saving therapeutics using its proprietary chromatographic purification technologies.
Ness Ziona , Israelwww.kamada.com
Labcyte Inc., headquartered in Sunnyvale, California, uses sound to move liquids for the compound management, geonomics, proteomics, particle manufacturing, encapsulation, imaging mass spectrometry and live-cell transfer fields.
Labopharm is a pharmaceutical company that develops improved formulations of currently marketed drugs, addressing the market's preference for drugs that offer simplified dosing regimens, improved efficacy or a reduced side effect profile.
Light Sciences Oncology, Inc. (LSO) is developing Light Infusion Therapy (Litx(TM)) to provide safer and more effective treatment to cancer patients.
Mast Therapeutics is a publicly traded biopharmaceutical company developing novel therapies for the treatment of sickle cell disease and cardiovascular disorders.
San Diego, CAwww.masttherapeutics.com
Medrobotics Corporation is a privately-held company that is developing and commercializing the Flex™ Robotic System, a robotic-assist platform that enables surgeons to gain single-site access and visualization to difficult-to-access anatomical locations.
MELA Sciences, Inc. (NASDAQ: MELA) is a medical device company focused on the commercialization of its flagship product, MelaFind®, a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations that uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin.
Melinta Therapeutics is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. A key initiative at Melinta is to develop a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections.
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.
Merrion Pharmaceuticals (www.merrionpharma.com) is a product development company focused on delivering innovation to the market by working on their own products and partnering to develop strategic products.
Dublin 24, Irelandwww.merrionpharma.com
Micell Technologies® is a cardiovascular company that is enhancing the performance of medical devices with innovative drug-delivery systems. By applying unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of bioabsorbable polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-eluting balloon and a fully absorbable stent for vascular interventions. The Company's patented processes and methods for medical device surface modification using supercritical fluids are focused on resolving known problems with current durable polymer-based drug-eluting technologies. The company's lead product candidate, MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System ("MiStent® SES") is a CE marked drug-eluting stent designed to merge the therapeutic efficacy potential of a sirolimus-eluting stent with the long-term safety characteristics of a bare-metal stent.
Navidea Biopharmaceuticals, Inc. is a biomedical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents.
Grand Prairie, TXwww.neostx.com
Neosil, Inc. is a dermatology-focused pharmaceutical company with a developed topical hair growth product and that is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use.
NetBio, Inc. is the leading provider of the full set of technologies and products for the emerging field of Rapid DNA Analysis (RDA), which enables the identification of the most informative subset of a given human or pathogen genome, allowing end users to make decisions in real time.
Neuralstem's (NYSE MKT: CUR) patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia.
NextWave is an emerging specialty pharmaceutical company primarily focused on the development and commercialization of unique products for the treatment of cardiovascular and CNS diseases.
NinePoint Medical is positioned to improve patient care through the development of medical devices that enable high resolution in-vivo imaging.
Novasys Medical, Inc. develops innovative therapies in women's health, initially focusing on the development and commercialization of the Renessa™ System, a proprietary, non-surgical approach to the treatment of female stress urinary incontinence (SUI).
Novelion Therapeutics, Inc. is an emerging biopharmaceutical company focused on the development and commercialization of novel, breathrough theraputics to treat debilitation and often fatal diseases.
NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and high-throughput amplification and labeling systems to enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies.
San Carlos , CAwww.nugeninc.com
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders.
OMRIX develops and markets innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how.
Omthera Pharmaceuticals, Inc. is an emerging specialty pharmaceuticals company, led by a team of experts with exceptional experience in developing new therapies for lipid disorders, that focuses its efforts on the clinical development of new therapies for dyslipidemia.
Optiscan Biomedical is a medical device company that specializes in glucose monitoring.
Oraya Therapeutics, Inc. is a privately-held company that develops innovative and non-invasive therapies for diseases of the eye.
Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture, and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers.
Paratek Pharmaceuticals, Inc. is a privately held biopharmaceutical company engaged in the discovery and commercialization of new therapeutics that treat life threatening infectious and other serious diseases.
PhaseRx is a preclinical biopharmaceutical company dedicated to developing products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). The Company’s i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform. PhaseRx is headquartered in Seattle, Wash. For more information, visit http://www.phaserx.com.
Portola is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis (blood clots), other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options.
San Francisco , CAwww.portola.com
Power Medical Interventions (PMI) is a medical device company that designs, develops, and markets new computerized and reusable devices and methods for delivering staples during surgery - a concept that has now taken form in the revolutionary SurgASSIST System, the world's first computer-mediated transection and anastomosis device.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF). In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use in the clinic and the home. Quanta’s lead product SC+ is the only high performance, portable, easy-to-use haemodialysis system which empowers patients through patient led care. Quanta, based in Alcester, UK, was founded in 2008 and has attracted funding from a group of leading investors including: NBGI Ventures, Wellington Partners, Seroba Kernel, b-to-v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as IMI plc.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant commercial unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more.
QuatRx Pharmaceuticals Company is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
Ann Arbor, MIwww.quatrx.com
Recoly N.V. is a privately-held biotechnology company in the business of developing or acquiring platform technologies for use in the health care industry.
1180, Brussels, Belgiumwww.recoly.com
Revance Therapeutics, Inc. is a privately held specialty biopharmaceutical company that has developed the proprietary TransMTSTM platform technology which enables local, targeted delivery of large macromolecules across skin.
Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia.
Savara Pharmaceuticals is a U.S.-based emerging pharmaceutical development company with an affiliate site in Denmark. The company is focused on advancing a pipeline of novel inhalation therapies for the treatment of patients with rare pulmonary conditions.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs.
Jersey City, NJwww.scynexis.com/
Singulex is a commercial stage company pioneering Next Generation Immunodiagnostics (NGI). Singulex’s proprietary Single Molecule Counting technology is the backbone of NGI, and provides unprecedented ultra-sensitivity in the precision measurement of biomarkers.
Sirtris Pharmaceuticals is a biopharmaceutical company developing and commercializing novel therapeutics that modulate sirtuins, a recently discovered family of enzymes that promotes the body's natural defense against disease.
SonaCare Medical is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies.
Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation, and autoimmune diseases.
San Diego, CAwww.sorrentotherapeutics.com
Tethys is a cardiometabolic diagnostics company that creates and commercializes breakthrough biomarker-based blood tests that predict imminent disease risk and enable targeted intervention to preempt the onset of chronic conditions such as type 2 diabetes.
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), is a specialty pharmaceutical company developing novel formulations of proven CNS agents to provide meaningful new patient benefits.
Point Richmond, CAwww.transcept-pharma.com
TransMedics is a medical technology company dedicated to extending the life saving benefits of organ transplantation to patients suffering from end-stage organ failure.
uniQure is a world leader in the research and early development of human gene based therapies.
United Orthopedic Group is a rapidly growing global orthopedic company with diverse operations all designed to provide outstanding service to its orthopedic physician customers.
ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer.
Oakwood Village, OHwww.viewray.com
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism and in patients who experience hypoglycemia following gastric bypass surgery. For more information, visit www.xoma.com.
Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company’s proprietary transdermal delivery system.